

Chronic GI Motility Agents



Please fax this completed form to (866) 399-0929 OR mail to: Envolve Pharmacy Solutions PA Department | 5 River Park Place East, Suite 210 | Fresno, CA 93720.

Date of request:	Reference #:		MAS:			
Patient	Date of birth		ProviderOne ID or Coordinated Care ID			
Pharmacy name	Pharmacy NPI	Telephone number		Fax number		
Prescriber	criber Prescriber NPI Te		phone number Fax number			
Medication and strength		Dire	ections for use		Qty/Days supply	
1. Is this request for a continuation of existing therapy? Yes No						
 2. If this request is for a continuation of therapy, is there documentation showing positive clinical benefit of one of the following (check all that apply): A ≥30% reduction in average daily abdominal pain score compared to baseline Documentation of ≥3 or more spontaneous bowel movements per week Increase of ≥1 spontaneous bowel movement per week compared to baseline Reduction in number of days per week with at least 1 stool that has a type 6 or 7 consistency according to the Bristol Stool Form Scale (BSFS) compared to baseline. 						
 Indicate patient's diagnosis: Irritable bowel syndrome with constipation (IBS-C) Chronic idiopathic constipation (CIC) Opioid-induced constipation (OIC) with chronic non-cancer pain Severe diarrhea-prominent irritable bowel syndrome (IBS) Irritable bowel syndrome with diarrhea (IBS-D) Opioid-induced constipation in patients with advanced illness or pain caused by active cancer requiring opioid dosage escalation for palliative care Other. Specify: 						
4. Does patient have history of a known or suspected GI obstruction? Yes No						
 5. Does the patient have a history of failure, contraindication or intolerance to ≥ 2 week trial of any of the following conventional therapies? (check all that apply)						
For tegaserod (Zelnorm) answer the following:						
6. Does the patient have a history of any of the following (check all that apply): Abdominal adhesions Angina Myocardial Infarction Gallbladder disease Transient Ischemic attack Other forms of intestinal ischemia						
7. What is the patients eGFR? mL/min						

For diagnosis of irritable bowel syndrome with diarrhea (IBS-D) answer the following:					
8. Does the patient have a history of any of the following (check all that apply):					
Alcoholism or consumption of more than 3 alcoholic drinks daily					
Biliary duct obstruction	Cholecystectom				
Chronic or severe consti		•			
Severe hepatic impairme		di disease or dysfunction			
Severe nepatie impairine	in (cima rugire)	ar disease or dystatiction			
For diagnosis of severe diarrhea-prominent irritable bowel syndrome (IBS) answer the following:					
9. Does the patient have any of the following symptoms? (check all that apply)					
Frequent and severe abdominal pain/discomfort					
Frequent bowel urgency or fecal incontinence					
Disability or restriction of daily activities due to IBS-D					
10. Does the patient have a history of any of the following (check all that apply):					
Crohn's disease or ulcerative colitis Diverticulitis					
Toxic megacolon Gastrointestinal perforation or adhesions					
☐ Ischemic colitis ☐ Impaired intestinal circulation					
Thrombophlebitis or hypercoagulable state Severe hepatic impairment					
Duestide the following required decomposite tion.					
Provide the following required documentation:					
• Chart notes					
Continuation of therapy requests: Documentation of positive clinical benefit, including baseline measures					
Prescriber signature	Prescriber specialty	Date			

Envolve Pharmacy Solutions will respond via fax or phone within 24 hours of receipt of the request. Requests for prior authorization must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)